Biogen soars 43% after its Alzheimer's drug helps slow down cognitive decline in late-stage study
JPMorgan estimates the Alzheimer's drug could generate between $6 billion and $10 billion in peak sales.
Full Article
Biogen soars 43% after its Alzheimer's drug helps slow down cognitive decline in late-stage study
Business Insider
0 shares
1 views
You might like
Related news coverage
Alzheimer's drug shows promise in early results of study
SeattlePI.com
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its..
-
Biogen shares soar on Alzheimer's drug developments
FOXNews.com
-
News24.com | Alzheimer's drug succeeds in slowing cognitive decline, makers Eisai and Biogen say
News24
-
New Alzheimer's drug slows cognitive decline by 27%, clinical trial finds
Business Insider
-
Experimental Alzheimer’s drug slows cognitive decline in trial, firms say
Brisbane Times
Advertisement
More coverage
Alzheimer’s Drug Slows Cognitive Decline in Key Study
Biogen and Eisai reported the finding from a large late-stage clinical trial of lecanemab, a drug they are developing.
NYTimes.com